▟ Vinebot intrinsic value, daily

← back

TECH Bio-Techne

pharma · valued with opus low conviction · deep-dived 2026-10-27

STRONG SELL
Intrinsic value$22.46
Price (at call)$72.69
Margin of safety -69.1%
vs market (rating basis) -45.1%

Durable reagent moat, but the price still assumes a growth recovery that flat revenue hasn't confirmed.

The story

Bio-Techne sells research reagents (proteins, antibodies), spatial biology tools and diagnostics. The reagent franchise has a real moat: scientists stick with validated, often-cited inputs, which keeps gross margins high. Revenue has been flat at about $1.22B because biopharma and academic funding are weak. GAAP operating margin has recovered from 8.8% to 20.6%, but growth has not returned yet. This is a mature, high-quality business waiting for its end markets to recover, not an early-stage compounder.

Growth, margin, risk and horizon are unchanged. Revenue is still flat, and the margin rebound to 20.6% supports the existing 30% target rather than a higher one. I raised sales-to-capital from 1.2 to 1.5 (+25%) because capex is about $0.03B against $0.10B of D&A, so organic reinvestment is light. The reported 0.53 ratio is weighed down by acquisition goodwill, not by what it costs to grow. The market price implies sustained growth of 8-10%, and I won't assume that until the revenue data shows it.

Value drivers

Revenue growth (Y1)4.0%
Terminal growth3.5%
Forecast horizon10y
Target operating margin30.0%
Years to target margin5
Sales-to-capital1.50
Beta1.00
Failure probability1.0%
Cost of capital (WACC)9.4%
Terminal WACC9.4%

Valuation bridge

PV of explicit FCFF1.71B
PV of terminal value1.78B
Equity value3.52B
÷ shares → per share$22.46

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 1.26B 4.0% 22.5% 214.65M 32.40M 182.25M 166.58M
2 1.31B 3.9% 24.4% 241.78M 33.23M 208.55M 174.23M
3 1.36B 3.9% 26.2% 270.56M 34.05M 236.51M 180.60M
4 1.42B 3.8% 28.1% 301.06M 34.87M 266.19M 185.78M
5 1.47B 3.8% 30.0% 333.32M 35.68M 297.63M 189.87M
6 1.53B 3.7% 30.0% 345.72M 36.49M 309.24M 180.31M
7 1.58B 3.7% 30.0% 358.40M 37.28M 321.12M 171.14M
8 1.64B 3.6% 30.0% 371.34M 38.06M 333.28M 162.35M
9 1.70B 3.6% 30.0% 384.55M 38.83M 345.72M 153.93M
10 1.76B 3.5% 30.0% 398.01M 39.58M 358.42M 145.86M

Key risks

  • Prolonged weakness in biopharma and academic funding (NIH budget cuts, biotech capital scarcity) keeps growth near zero
  • Spatial biology and diagnostics acquisitions fail to earn their cost of capital, leading to further impairments and margin swings
  • Valuation multiple compresses if a recovery is delayed past 2027

Catalysts

  • Biotech funding and pharma R&D spending recover, bringing reagent volumes back to high single-digit growth
  • Margin expansion toward 30%+ as one-time restructuring costs fade and spatial and cell-therapy lines scale

History

DatePriceIntrinsicMoSRating
2026-10-27$72.69 $22.46 -69.1% STRONG SELL
2026-09-23$72.55 $22.17 -69.4% SELL
2026-08-20$72.48 $5.31 -92.7% STRONG SELL
2026-07-17$71.77 $16.29 -77.3% STRONG SELL
2026-06-23$56.26 $17.85 -68.3% SELL